In terms of response, it met its primary end point in all 3 doses. 1 The ORR was 50% or higher [in all 3 groups]. The dose of ...
Clinical Trials Arena on MSN16h
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase IIIUK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback